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Background: Breast cancer is one of the most common malignancies in women. Genome-wide association studies have identified FGFR2 as a
breast cancer susceptibility gene. Common variation in other fibroblast growth factor (FGF) receptors might also modify risk. We tested this
hypothesis by studying genotyped single-nucleotide polymorphisms (SNPs) and imputed SNPs in FGFR1, FGFR3, FGFR4 and FGFRL1 in the Breast
Cancer Association Consortium.
Methods: Data were combined from 49 studies, including 53835 cases and 50156 controls, of which 89050 (46450 cases and 42600 controls) were of
European ancestry, 12893 (6269 cases and 6624 controls) of Asian and 2048 (1116 cases and 932 controls) of African ancestry. Associations with risk of
breast cancer, overall and by disease sub-type, were assessed using unconditional logistic regression.
Results: Little evidence of association with breast cancer risk was observed for SNPs in the FGF receptor genes. The strongest evidence in
European women was for rs743682 in FGFR3; the estimated per-allele odds ratio was 1.05 (95% confidence interval¼ 1.02–1.09, P¼ 0.0020), which is
substantially lower than that observed for SNPs in FGFR2.
Conclusion: Our results suggest that common variants in the other FGF receptors are not associated with risk of breast cancer to the degree
observed for FGFR2.
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Breast cancer is a complex disease, with multiple genetic and
environmental factors involved in its etiology. Rare mutations in
the DNA repair genes BRCA1 and BRCA2 confer a high lifetime
risk of breast cancer (Antoniou et al, 2003) and are routinely
screened for in women with a strong family history of the disease.
Studies focused on other DNA repair genes have led to the
discovery that rare coding variants in CHEK2, ATM, BRIP1 and
PALB2 (Swift et al, 1987; Meijers-Heijboer et al, 2002; Seal et al,
2006; Rahman et al, 2007) are associated with moderately increased
breast cancer risk. However, few, if any, candidate-gene- or
pathway-based association studies have identified convincing
associations with breast cancer risk for common genetic variants
(The Breast Cancer Association Consortium, 2006). In contrast,
empirical genome-wide association studies (GWAS) have proven
to be a successful approach to identify common variants associated
with small increases in risk, with more than 70 identified in
this way to date (Easton et al, 2007; Hunter et al, 2007; Stacey
et al, 2007, 2008; Ahmed et al, 2009; Thomas et al, 2009; Zheng
et al, 2009; Antoniou et al, 2010; Turnbull et al, 2010; Cai et al,
2011; Fletcher et al, 2011; Haiman et al, 2011; Ghoussaini
et al, 2012; Siddiq et al, 2012; Bojesen et al, 2013; Garcia-Closas
et al, 2013; Michailidou et al, 2013). For the great majority
of these associations, the causal variant(s), and even the causal
gene, are unknown; thus, the identification of novel candidate
genetic susceptibility pathways through this approach is not
straightforward.
An intronic variant in the FGFR2 gene was one of the first
single-nucleotide polymorphisms (SNPs) identified by GWAS as
tagging a breast cancer susceptibility locus (Easton et al, 2007;
Hunter et al, 2007). It is now well-established that the minor allele
of this SNP is associated with increased risk of breast cancer,
particularly estrogen receptor (ER)-positive disease (Garcia-Closas
et al, 2008). Fine-mapping of the region has suggested that at least
one causal variant is located in intron 2 of FGFR2 (Easton et al,
2007; Udler et al, 2009), and functional studies have proposed that
rs2981578 affects FGFR2 expression (Meyer et al, 2008; Udler et al,
2009; Huijts et al, 2011). These findings strongly suggest that
FGFR2 is a breast cancer susceptibility gene.
FGFR2 is a fibroblast growth factor (FGF) receptor gene; the
amino-acid sequence of the protein it encodes is highly conserved
across all FGF receptors. The other FGF receptor genes and other
genes acting downstream of them in the FGF pathway may also be
implicated in the development of breast cancer, although
associations with disease risk have not been assessed comprehen-
sively by a study with adequate sample size to detect odds ratios
(ORs) of the magnitude observed for SNPs in FGFR2.
We hypothesised that common variants in other genes in the
FGF pathway, and in the other FGF receptor genes in particular,
might also confer increased breast cancer risk. The primary aim
of our investigation was to comprehensively assess associations
between breast cancer risk and common variation in the FGF
receptor genes FGFR1, FGFR3, FGFR4 and FGFRL1 by genotyping
selected tag-SNPs in the Breast Cancer Association Consortium
(BCAC). A secondary objective was to assess common variants in
other genes in the FGF pathway based on a two-stage design.
MATERIALS AND METHODS
Participants. Study participants were women from 49 studies
participating in BCAC: 38 from populations of predominantly
European ancestry, 9 of Asian women and 2 of African–American
women (Table 1 and Supplementary Table 1). The majority were
population-based or hospital-based case–control studies, but some
studies selected subjects based on age or oversampled for cases
with a family history or bilateral disease. Cases and controls from
the CNIO-BCS were also studied in a previous assessment of
selected genes in the FGF pathway. All study participants gave
informed consent and each study was approved by the corresponding
local ethics committee.
Gene and SNP selection. Ingenuity Pathways Analysis and
selected publications (Eswarakumar et al, 2005; Presta et al,
2005; Chen & Forough, 2006; Schwertfeger, 2009) were used to
identify genes reported to be involved downstream of the FGF
genes in the FGF pathway, particularly those related to angiogenesis.
A total of 39 genes, including the FGF receptors FGFR1 (located at
8p11.22), FGFR2 (10q26.13), FGFR3 (4p16.3), FGFR4 (5q35.2)
and FGFRL1 (4p16.3), was selected for tagging. Single-
nucleotide polymorphisms with minor allele frequency (MAF)
45% in the coding and non-coding regions, and within 5 kb
upstream and 5 kb downstream of each gene, were identified using
HapMap CEU genotype data and dbSNP 128 as reference. The
minimum number of tag-SNPs were then selected among all
identified SNP using Haploview (Barrett et al, 2005) based on the
following criteria: r240.8 and Illumina assay score 40.60. A total
of 384 SNPs tagging 39 genes was genotyped in the CNIO-BCS,
324 of which were successfully genotyped (Supplementary
Table 2). The 31 SNPs tagging genes FGFR1, FGFR3, FGFR4 and
FGFRL1 were all genotyped in BCAC, along with a further 26
of the 324 tag-SNPs. The latter group comprised SNPs selected
based on evidence of association with breast cancer under a
log-additive model in the Stage 1 CNIO-BCS. Single-nucleotide
polymorphisms in FGFR2 were not considered, as all were
included as part of a separate fine-mapping study (Meyer et al,
submitted). Results from Stage 1 are summarised in Supplementary
Table 2.
Genotyping. Genotyping of the 57 SNPs in the BCAC samples
was conducted using a custom Illumina Infinium array (iCOGS) in
four centers, as part of a multi-consortia collaboration (the
Collaborative Oncological Gene–Environment Study, COGS) as
described previously (Michailidou et al, 2013). Genotypes were
called using Illumina’s proprietary GenCall algorithm.
For the genotyping of the 384 SNPs in the Stage 1 CNIO-BCS,
genomic DNA was isolated from peripheral blood lymphocytes using
automatic DNA extraction (MagNA Pure, Roche Diagnostics,
Indianapolis, IN, USA) according to the manufacturer’s recom-
mended protocols. This DNA was quantified using Picogreen
(Invitrogen, Life Technologies, Grand Island, NY, USA) and for
each sample a final quantity of 250 ng was extracted and used for
GoldenGate genotyping with VeraCode Technology (Illumina Inc.,
San Diego, CA, USA). Samples were arranged on 25 96-well plates
containing one negative control and at least one study sample in
duplicate. Three Centre d’Etude du Polymorphisme Humain (CEPH)
trios were used as internal intra- and inter-plate duplicates and to
check for Mendelian segregation errors. DNA was extracted,
quantified, plated and genotyped at the Spanish National Genotyping
Centre (CeGen), Madrid, Spain. All genotypes were determined for
each SNP and each plate using manual clustering. Single-nucleotide
polymorphisms with call rateo90% were excluded, as were samples
with no-calls for more than 20% of included SNPs.
Statistical methods. For each SNP, we estimated ORs and 95%
confidence intervals (CIs) using unconditional logistic regression.
For the analysis of BCAC data, we considered per-allele and co-
dominant models using common-allele homozygotes as reference
and including study and ethnicity-specific principal components as
covariates, as previously described (Michailidou et al, 2013).
Departure from the Hardy–Weinberg equilibrium (HWE) was
tested for in controls from individual studies using the genhwi
module in STATA 11.2 (College Station, TX, USA). A study-
stratified w2 test (1df) was applied across studies (Haldane, 1954;
Robertson & Hill, 1984). Between-study heterogeneity in ORs was
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assessed for each of the three broad racial groups using the metan
command in STATA to meta-analyse study-specific per-allele log-OR
estimates and generate I2 statistics; values greater than 50% were
considered notable (Higgins & Thompson, 2002). Odds ratios specific
to disease subtypes defined by ER, PR and HER2 status (positive and
negative) were estimated separately for each ethnic subgroup using
polytomous logistic regression with control status as the reference
outcome. Differences in ORs by disease subtypes were assessed using a
likelihood ratio test (LRT). All statistical tests were two-sided.
The effective number of independent SNPs (VeffLi) was
estimated using the method described by Li & Ji (2005). This
method was applied via the web-interface matSpDlite (http://
gump.qimr.edu.au/general/daleN/matSpDlite/), based on the
observed correlations between SNPs (Nyholt, 2004). VeffLi was
then used to calculate a Bonferroni-corrected significance thresh-
old (a*). Power calculations were carried out using Quanto v1.2.4
(http://hydra.usc.edu/gxe/).
Single-nucleotide polymorphism imputation. The genotypes of
untyped SNPs were imputed based on data from the March 2012
release of the 1000 genomes project using IMPUTE v2.2. These
were converted to allele doses using the impute2mach function in
the GenABEL library in R (Aulchenko et al, 2007) and analysed
under a per-allele model. Imputed SNPs with an estimated MAF
o5% were excluded, as were SNPs with an imputation r2o80%.
RESULTS
All SNPs in the present analysis had overall call rates495%. Very
strong evidence of departure from HWE was observed for
rs34869253 for one study (pKarma, P¼ 3.3 10 21), which was
excluded from the subsequent analyses of that SNP. After quality
control, there were data available for 53 835 cases and 50 156
controls from BCAC, including 89 050 European women (46 450
cases and 42 600 controls), 12 893 Asian (6269 cases and 6624
controls) and 2048 African–American women (1116 cases and 932
controls) (Table 1).
Results from the analysis of the 31 tag-SNPs in FGFR genes
for white Europeans are summarised in Table 2. No strong
evidence of association was observed, although one SNP
(rs743682) in FGFR3 (MAF¼ 9%) was marginally significant
after correction for multiple testing based on a VeffLi of 23
(per-allele OR¼ 1.05, 95%CI¼ 1.02–1.09, P¼ 0.0020, a*¼ 0.0022).
All SNPs with an associated P-value o0.05 were intronic, with
the exception of rs1966265, which is a missense variant in
FGFR4. However, PolyPhen (http://genetics.bwh.harvard.edu/
pph2/) predicts this amino acid change to be benign, with a
score of 0.000. On the basis of ENCODE data, no SNP with an
associated P-value o0.05 was located in a region involved or
predicted to be involved in epigenetic regulation, nor at, or
within 2 kb of, a CpG island. For European women, we did not
observe any evidence of between-study heterogeneity for any
SNPs (I2p19%; PX0.15) and little evidence of differential
associations by disease subtypes defined by ER (PX0.036),
PR (PX0.084) or HER2 status (PX0.019).
We similarly observed little evidence of association with overall
breast cancer risk in Asian and African–American women
(Supplementary Tables 3 and 4, respectively). Nevertheless, a
consistent result was observed for Europeans and Asians for
rs1966265 in FGFR4. The estimated OR per risk (G) allele was 1.03
(95%CI¼ 1.01–1.05; P¼ 0.0060) for European women and 1.08
(95%CI¼ 1.03–1.14; P¼ 0.0036) for Asian women. There was no
evidence of heterogeneity by race for any of the 31 SNPs in FGF
receptors (I2¼ 18%; P¼ 0.14).
The SNPs genotyped were estimated to capture a variable
proportion of the common variation in the four genes considered,
as described in the 1000 genomes project; at r2X0.80, this coverage
was 75% for FGFR1, 77% for FGFR3, 66% for FGFR4 and 17% for
FGFRL1. This coverage was dramatically improved with the
inclusion of imputed common SNPs (with imputation r240.80)
to 95%, 93%, 97% and 84% for FGFR1, FGFR3, FGFR4 and
FGFRL1, respectively. No stronger evidence of association was
observed for any imputed SNPs (Supplementary Tables 5–8).
Finally, we observed little evidence of association for any of the
26 SNPs in other genes in the FGF pathway, selected based on
results from Stage 1 (Supplementary Table 9). The results were
consistent across the three ethnic groups considered and for
disease subtypes defined by ER, PR and HER2 expression.
It is noteworthy that strong association signals were observed in
the Stage 1 Spanish study for selected tag-SNPs rs10736303
(MAF¼ 0.49; per-allele OR¼ 1.37, 95% CI¼ 1.21–1.55, P¼ 2.8
 10 7), and rs2981582 (MAF¼ 0.40; per-allele OR¼ 1.35, 95%
CI¼ 1.19–1.53, P¼ 8.3 10 7), both in FGFR2.
DISCUSSION
In this multicentre case–control study, we comprehensively
assessed common variation in the FGF receptor genes FGFR1,
FGFR3, FGFR4 and FGFRL1 in 53 835 cases and 50 156 controls
and found little evidence of association with risk of breast cancer.
This is the largest study we know of assessing a family of genes via
a candidate approach based on the findings from GWAS.
A non-trivial issue in analyses of this kind is the establishment
of a statistical significance threshold that adequately controls the
proportion of false-positive findings. As permutation-testing was
not feasible due to the sample size and number of dummy variables
required to adjust for study, we dealt with the issue of non-
independence of multiple tests by estimating that the 31 tag-SNPs
represented an effective number of 23 independent variables, and
applying a Bonferroni correction accordingly. The association of
one SNP (rs743682) in FGFR3 for European women was found to
be statistically significant on this basis. However, the P-value
threshold applied is somewhat questionable in the context of the
total of more than 70 000 SNPs nominated for genotyping by
BCAC and the total 210 000 genotyped on the iCOGS array. Thus,
the current result is far from genome-wide statistical significance
and certainly requires independent replication. In any case, the
per-allele ORs for FGFR3_rs743682 (1.05, 95% CI¼ 1.02–1.09) and
FGFR4_rs1966265 (1.03, 95% CI¼ 1.01–1.05) appear to be
substantially lower than that for rs2981582 in FGFR2 (1.26, 95%
CI¼ 1.23–1.30) (Easton et al, 2007).
We estimated that for common SNPs (MAF 40.05) associated
with overall breast cancer risk in European women, we had greater
than 99% power to detect at genome-wide statistical significance
(Po5 10 8) a per-allele OR as low as 1.23 (the lower 95%
confidence limit for the OR for FGFR2_rs2981582). For a per-allele
OR as low as 1.05 and for SNPs with MAF of 0.10, 0.20 and 0.30,
the estimated power was 1%, 10% and 24%, respectively. That is,
our study provides strong evidence that common variation in
FGFR1, FGFR3, FGFR4 and FGFRL1 are not associated with breast
cancer risk to the degree observed for SNPs in FGFR2, although
associations of smaller magnitude may exist.
The hypothesis underlying our study was based on the
identification of a functional SNP in intron 2 of FGFR2
associated with breast cancer susceptibility (Easton et al, 2007;
Meyer et al, 2008; Udler et al, 2009; Huijts et al, 2011). A recent
study has subsequently identified three independent risk signals
within FGFR2, and uncovered likely causal variants and
functional mechanisms behind them (Meyer et al, 2013).
Although an association between these SNPs and expression of
FGFR2 has not been established, these results provide strong
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evidence that FGFR2 is the target gene, and it therefore seems
plausible that other FGF receptors or genes acting in the FGF
pathway might also be implicated in breast cancer risk. However,
we find little evidence that this is the case for the receptors, at least
not to the extent observed for common variants in FGFR2.
Admittedly, the degree to which common variation in the FGF
Table 1. Number of cases and controls included, by study
Study Country Controls Cases ERþ ER
White European women
Australian Breast Cancer Family Studya (ABCFS) Australia 551 790 456 261
Amsterdam Breast Cancer Study (ABCS) Netherlands 1429 1325 420 153
Bavarian Breast Cancer Cases and Controls (BBCC) Germany 458 564 460 83
British Breast Cancer Study (BBCS) UK 1397 1554 507 114
Breast Cancer In Galway Genetic Study (BIGGS) Ireland 719 836 495 154
Breast Cancer Study of the University Clinic Heidelberg (BSUCH) Germany 954 852 499 154
CECILE Breast Cancer Study (CECILE) France 999 1019 797 144
Copenhagen General Population Study (CGPS) Denmark 4086 2901 1919 357
Spanish National Cancer Centre Breast Cancer Study (CNIO-BCS) Spain 876 902 242 88
California Teachers Study (CTS) USA 71 68 0 17
ESTHER Breast Cancer Study (ESTHER) Germany 502 478 304 98
Gene–Environment Interaction and Breast Cancer in Germany (GENICA) Germany 427 465 328 119
Helsinki Breast Cancer Study (HEBCS) Finland 1234 1664 1295 237
Hannover-Minsk Breast Cancer Study (HMBCS) Belarus 130 690 37 0
Karolinska Breast Cancer Study (KARBAC) Sweden 662 722 338 63
Kuopio Breast Cancer Project (KBCP) Finland 251 445 304 97
kConFab/Australian Ovarian Cancer Study (kConFab/AOCS) Australia 897 613 162 59
Leuven Multidisciplinary Breast Centre (LMBC) Belgium 1388 2671 2071 379
Mammary Carcinoma Risk Factor Investigation (MARIE) Germany 1778 1818 1349 399
Milan Breast Cancer Study Group (MBCSG) Italy 400 488 149 42
Mayo Clinic Breast Cancer Study (MCBCS) USA 1931 1862 1486 295
Melbourne Collaborative Cohort Study (MCCS) Australia 511 614 352 119
Multi-ethnic Cohort (MEC) USA 741 731 415 87
Montreal Gene–Environment Breast Cancer Study (MTLGEBCS) Canada 436 489 421 64
Norwegian Breast Cancer Study (NBCS) Norway 70 22 0 22
Oulu Breast Cancer Study (OBCS) Finland 414 507 407 100
Ontario Familial Breast Cancer Registryb (OFBCR) Canada 511 1175 630 268
Leiden University Medical Centre Breast Cancer Study (ORIGO) Netherlands 327 357 211 70
NCI Polish Breast Cancer Study (PBCS) Poland 424 519 519 0
Karolinska Mammography Project for Risk Prediction of Breast Cancer (pKARMA) Sweden 5537 5434 3672 702
Rotterdam Breast Cancer Study (RBCS) Netherlands 699 664 368 131
Singapore and Sweden Breast Cancer Study (SASBAC) Sweden 1378 1163 663 144
Sheffield Breast Cancer Study (SBCS) UK 848 843 377 105
Studies of Epidemiology and Risk factors in Cancer Heredity (SEARCH) UK 8069 9347 5160 1181
Sta¨dtisches Klinikum Karlsruhe Deutsches Krebsforschungszentrum Study (SKKDKFZS) Germany 29 136 0 136
IHCC-Szczecin Breast Cancer Study (SZBCS) Poland 315 365 165 60
Triple Negative Breast Cancer Consortium Study (TNBCC) Various 542 881 0 881
UK Breakthrough Generations Study (UKBGS) UK 470 476 96 22
Asian women
Asian Cancer Project (ACP) Thailand 636 423 92 53
Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC) Japan 1376 694 395 139
Los Angeles County Asian-American Breast Cancer Case–Control (LAABC) USA 990 812 528 138
Malaysian Breast Cancer Genetic Study (MYBRCA) Malaysia 610 770 422 291
Shanghai Breast Cancer Genetic Study (SBCGS) China 892 848 510 276
Seoul Breast Cancer Study (SEBCS) South Korea 1129 1162 657 375
Singapore Breast Cancer Cohort (SGBCC) Singapore 502 533 272 108
IARC-Thai Breast Cancer (TBCS) Thailand 253 138 26 26
Taiwanese Breast Cancer Study (TWBCS) Taiwan 236 889 460 204
African
Southern Community Cohort Study (SCCS) USA 680 679 0 0
Nashville Breast Health Study (NBHS) USA 252 437 199 222
Total 50156 53835 30635 9120
Abbreviations: ER ¼ estrogen receptor-negative cases; ERþ ¼ estrogen receptor-positive cases.
aAustralian site of the Breast Cancer Family Registry.
bOntario site of the Breast Cancer Family Registry.
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receptor genes was tagged by the genotyped SNPs was good for
FGFR1, FGFR3 and FGFR4 and poor for FGFRL1, but substantial
improvement was afforded by imputation. Nevertheless, it is possible
that common variation not captured by the genotyped or imputed
SNPs may be associated with breast cancer risk. It is also possible that
these genes may be implicated in disease susceptibility via regulatory
mechanisms involving variants outside the chromosomal boundaries
defined for each gene considered. That said, few studies have assessed
common variation in candidate genes to this extent, in terms of both
gene coverage and sample size.
The power of our study was much lower for Asian and
African–American women; however, our primary focus on
European women is consistent with our hypothesis, based on
the previous finding in FGFR2 in this population. Our study was
also limited by the power and gene coverage of the stage 1
component which assessed tag-SNPs in the selected genes of the
FGF pathway. Therefore, no conclusions can be drawn about
the potential implication of common variation in these genes
in breast cancer susceptibility. Nevertheless, we checked
the chromosomal locations of the 76 established risk-associated
loci (http://www.nature.com/icogs/primer/shared-susceptibility-
loci-for-breast-prostate-and-ovarian-cancers/) and found that
none were located within 10 kb of any of the 39 genes considered,
with the exception of the FGFR2 locus.
In conclusion, in this, possibly the largest candidate-gene
association study carried out to date, we have observed little evidence
of association between common variation in the FGFR1, FGFR3,
FGFR4 and FGFRL1 genes and risk of breast cancer. Our results
suggest that common variants in these FGF receptors are not
associated with risk of breast cancer to the degree observed for FGFR2.
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rs4733930 GA 0.42 1.00 (0.97–1.03) 1.04 (1.00–1.08) 1.02 (1.00–1.04) 0.11 1.03 (0.99–1.07) 1.02 (1.00–1.04) 0.67
rs4733946 CA 0.08 1.00 (0.97–1.03) 1.04 (1.00–1.08) 1.02 (1.00–1.04) 0.11 1.01 (0.95–1.08) 1.04 (1.00–1.09) 0.39
rs6474354 GA 0.21 0.98 (0.95–1.01) 0.99 (0.92–1.05) 0.98 (0.96–1.01) 0.18 0.96 (0.92–1.01) 0.98 (0.96–1.01) 0.37
rs6996321 GA 0.39 1.01 (0.98–1.04) 1.00 (0.96–1.04) 1.00 (0.98–1.02) 0.95 1.00 (0.97–1.04) 0.99 (0.97–1.02) 0.54
rs6983315 GA 0.44 1.01 (0.97–1.04) 0.98 (0.94–1.02) 0.99 (0.97–1.01) 0.39 0.97 (0.93–1.00) 0.99 (0.97–1.02) 0.13
rs7012413 GA 0.30 1.00 (0.97–1.02) 0.99 (0.95–1.04) 1.00 (0.98–1.02) 0.69 1.00 (0.97–1.04) 1.00 (0.98–1.02) 0.82
FGFR3
rs12502543 GA 0.10 1.04 (1.01–1.08) 1.10 (0.96–1.25) 1.04 (1.01–1.08) 0.0076 0.99 (0.93–1.05) 1.06 (1.02–1.10) 0.036
rs2234909 AG 0.14 0.99 (0.95–1.02) 0.97 (0.88–1.07) 0.99 (0.96–1.01) 0.29 0.99 (0.94–1.04) 0.98 (0.95–1.02) 0.77
rs3135848 AG 0.28 1.02 (0.99–1.04) 1.02 (0.96–1.07) 1.01 (0.99–1.03) 0.31 1.00 (0.96–1.04) 1.01 (0.99–1.04) 0.55
rs743682 GA 0.09 1.05 (1.01–1.09) 1.16 (1.00–1.34) 1.05 (1.02–1.09) 0.0020 1.01 (0.95–1.08) 1.06 (1.02–1.10) 0.24
rs746779 GA 0.18 0.99 (0.96–1.02) 0.98 (0.90–1.06) 0.99 (0.96–1.01) 0.29 1.00 (0.95–1.05) 0.98 (0.95–1.01) 0.48
FGFR4
rs1076891 GA 0.06 1.03 (0.99–1.08) 0.99 (0.81–1.22) 1.03 (0.99–1.07) 0.14 1.06 (0.98–1.14) 1.01 (0.97–1.06) 0.25
rs1966265 GA 0.23 0.97 (0.94–1.00) 0.93 (0.88–0.99) 0.97 (0.95–0.99) 0.0060 0.98 (0.94–1.03) 0.97 (0.95–1.00) 0.54
rs2456173 GA 0.21 1.00 (0.97–1.03) 0.99 (0.92–1.05) 0.99 (0.97–1.02) 0.66 0.98 (0.94–1.02) 1.00 (0.98–1.03) 0.34
rs376618 AG 0.24 1.00 (0.97–1.03) 0.96 (0.91–1.02) 0.99 (0.97–1.01) 0.33 0.97 (0.93–1.01) 0.99 (0.97–1.02) 0.29
rs641101 GA 0.31 1.01 (0.98–1.04) 0.99 (0.94–1.03) 1.00 (0.98–1.02) 0.98 0.99 (0.95–1.03) 1.00 (0.98–1.02) 0.56
rs6556301 CA 0.36 0.99 (0.97–1.02) 0.96 (0.92–1.00) 0.98 (0.97–1.00) 0.13 0.99 (0.95–1.02) 0.98 (0.96–1.01) 0.84
FGFRL1
rs34869253 AG 0.43 1.00 (0.97–1.04) 1.00 (0.96–1.04) 1.00 (0.98–1.02) 0.96 0.98 (0.94–1.01) 0.99 (0.97–1.01) 0.52
rs3755955 GA 0.16 1.00 (0.97–1.03) 1.02 (0.94–1.11) 1.00 (0.98–1.03) 0.82 1.00 (0.95–1.05) 1.00 (0.97–1.03) 0.83
rs4505759 GA 0.30 0.99 (0.96–1.02) 0.98 (0.93–1.03) 0.99 (0.97–1.00) 0.38 1.00 (0.96–1.04) 0.99 (0.97–1.02) 0.78
rs4647932 GA 0.06 1.04 (0.99–1.08) 0.98 (0.80–1.20) 1.03 (0.99–1.07) 0.14 1.06 (0.98–1.14) 1.02 (0.97–1.06) 0.31
rs6855233 AG 0.29 0.99 (0.97–1.02) 1.03 (0.98–1.08) 1.01 (0.98–1.03) 0.62 0.98 (0.94–1.02) 1.00 (0.98–1.03) 0.31
rs748651 AG 0.48 1.00 (0.97–1.03) 1.02 (0.98–1.06) 1.01 (0.99–1.03) 0.31 1.03 (0.99–1.07) 1.01 (0.98–1.03) 0.22
Abbreviations: SNP¼ single-nucleotide polymorphism; FGF¼ fibroblast growth factor; OR¼odds ratio where A is the common allele, a is the rare allele and both Aa and aa are compared with
AA genotypes; CI¼ confidence interval; MAF¼minor allele frequency; P¼P-value for the per-a-allele model; ER ¼ results (per a-allele) for risk of estrogen receptor-negative disease;
ERþ ¼ results (per a-allele) for risk of estrogen receptor-positive disease; P-het¼P-value for heterogeneity by disease sub-type defined by estrogen receptor status.
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